Novel bifunctional anthracycline and nitrosourea chemotherapy for human bladder cancer: Analysis in a preclinical survival model

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1315-1319

  Glaves, Dorothy ^a   Murray, Michael K ^a   Raghavan, Derek ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; NITROSOUREA DERIVATIVE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; ENZYME INHIBITION; GROWTH INHIBITION; INTERCALATION COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARMUSTINE; DOXORUBICIN; FEMALE; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NITROSOUREA COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; URINARY BLADDER NEOPLASMS;

EID: 0029757387     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Raghavan, D., Shipley, W., Garnick, M. B., Russell, P. J., and Richie, J. P. Biology and management of bladder cancer. N. Engl. J. Med., 322: 1129-1138, 1990.
2. Sternberg, C. N., and Scher, H I. Advances in the treatment of urothelial tract tumors. Urol. Clin. North Am., 14: 373-387, 1987.
3. Geller, N. J., Sternberg, C N., Penenberg, D., Scher, H., and Yagoda, A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer (Phila.), 67: 1525-1531, 1991.
4. Loehrer, P. J., Sr., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., Lowe, B. A., Blumenstein, B., and Trump, D. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study. J. Clin. Oncol., 10: 1066-1073, 1992.
5. Levine, E., and Raghavan, D. MVAC for bladder cancer - time to move forward again. J. Clin. Oncol., 11: 387-389, 1993.
6. Israel, M., Seshadri, S , Koseki, K., Potmesil, M., Kirschenbaum, S., Silber, R., Bodley, A., Liu, L. F., and Brent, T. P. New anthracycline analogues directed against DNA topoisomerase II. In: H Tapiero, J. Robert, and T. J. Lampidis (eds.), Anticancer Drugs. Colloque INSERM, Vol. 191, pp. 39-47. Montrouge, France: John Libbey Eurotext Ltd., 1989
7. Israel, M., and Seshadri, S. U.S. Patent 4,973,675. November 1990.
8. Russell P. J., Wass, J., Lukeis, R., Garson O. M., Jelbart, M., Wills, E. J., Philips, J., Brown, J. L., Carrington, N., Vincent P., and Raghavan, D. Characterization of cell lines derived from a human bladder transitional cell carcinoma, UCRU-BL13, showing multiple aneuploidy. Int. J. Cancer, 44: 276-285, 1989.
9. Perez, R., Godwin, A. K , Handel, L. M., and Hamilton, T. C. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays in human ovarian carcinoma cell lines. Eur. J. Cancer, 29A: 395-399, 1993.
10. Keane, T. E., Gingrich, J. R., Rosner, G., Webb, K. S., Poulton, S. H., and Walther, P. J. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res., 54: 475-481, 1994.
11. Raghavan, D., DeBruyne, F., Herr, H., Jocham, D., Kazikoe, T., Okajima, E., Sandberg, A., and Tannock, I. Experimental models of bladder cancer: a review. Prog. Clin. Biol. Res., 221: 171-208, 1986.
12. Johansen, P. B. Doxorubicin pharmacokinetics after intravenous and peritoneal administration in the nude mouse. Cancer Chemother. Rep., 5: 267-270, 1981.
13. Greene, R. F., Collins, J. M , Jenkins, J. F., Speyer, J. L., and Myers, C. E. Plasma pharmacokinetics of Adriamycin and Adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res., 43: 3417-3421, 1983.
14. Israel, M., Sweatman, T. W., and Seshadri, R. 2-Chloroethylnitrosoureidodaunorubicin (AD312) pharmacokinetics in the rat. Proc. Am. Assoc. Cancer Res., 31: 383, 1990.
15. Schabel, F. M., Jr. BCNU [1,3-bis-(chloroethyl)-1-nitrosourea]: development, antitumor activity, and mechanism of action. In: S K. Carter (ed.), Proceedings of the Chemotherapy Conference on the Chemotherapy of Solid Tumors, an Appraisal of 5-Fluorouracil and BCNU, pp. 159-180. Bethesda, MD: Cancer Therapy Evaluation Branch, National Cancer Institute, 1970.
16. Russell, P. J., Raghavan, D., Gregory, P., Philips, J., Wills, E. J , Jelbart, M., Wass, J., Zbroja, R. A., and Vincent P. C. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res., 46: 2035-2040, 1986.
17. Raghavan, D., Russell, P. J., and Brown, J. L. Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer. Semin. Surg. Oncol., 8: 279-284, 1992.
18. Russell, P. J., Raghavan, D., Philips, J., and Gregory, P Applications of the xenograft as a model of invasive transitional cell carcinoma of the bladder. Prog. Clin. Biol. Res., 260: 167-181, 1988.
19. Israel, M., Koseki, K., and Seshadri, S. Further in vivo antitumor studies with 2-chloroethylnitrosoureidodaunorubicin (AD312) in murine P388 leukemia systems. Proc. Am. Assoc. Cancer Res., 32: 404, 1991.
20. Brown, J. L., Russell, P. J., Wotherspoon, J., and Raghavan, D. Clonal analysis of a bladder cancer cell line: an experimental model of tumor heterogeneity. Br. J. Cancer, 61: 369-376, 1990